Summarized by Masters of Longevity from Nature - Main.
Report on a phase III trial showing a personalized mRNA cancer vaccine given with checkpoint blockade substantially lowered melanoma recurrence risk versus checkpoint blockade alone.
Key Takeaways
- A personalized mRNA vaccine plus pembrolizumab cut melanoma recurrence or death by 42%.
- Researchers sequenced each tumour to create individualized vaccines targeting neoantigen mutations.
- No major harmful side effects were reported so far, but longer follow-up is required.
